Clinical Trials · NCT07621419
Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin
- Phase
- N/A
- Recruitment status
- Recruiting
- Sponsor
- Hospital Italiano de Buenos Aires
- Enrollment
- 145
- Start date
- Aug 2025
- Locations
- 2 sites, Argentina
- Primary endpoint
- Change in glycated hemoglobin (HbA1c) levels from baseline to 3, 6, and 12 months of follow-up.